Skip to main content
Clinical Trials/TCTR20190205002
TCTR20190205002
Recruiting
Phase 4

Effects of Vitamin C, Vitamin D3, Coenzyme Q10 and antioxidant formula of different supplement forms on micronutrient, biomarker blood levels and quality of life.

A0 sites72 target enrollmentFebruary 5, 2019

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Different formula of supplement on micronutrient&#44
Sponsor
A
Enrollment
72
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 5, 2019
End Date
June 30, 2019
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
A

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects aged ≥ 18 years who visit Vital\-life wellness center for micronutrient level assessment and decide to receive either Vitamin C, Vitamin D3, CO\-Q10 and antioxidant formula of HCK® or The original VTL supplement of Vitamin C, Vitamin D3, CO\-Q10 and antioxidant or no supplement after discussion for possible treatment options with physician as usual practice
  • 2\.Subjects found to have low level of 25\-(OH)D3/D2 (having 25\-(OH)D3/D2 level 20\-29 ng/ml) with the symptoms or feelings of low energy, lack of vitality or tiredness
  • 3\.Subjects who have not taken coenzyme Q10, vitamin C, vitamin D3, vitamin E, carotenoids, and flavonoids for at least 3 months and vitamin A for at least 6 months
  • 4\.Willing and able to comply with study procedure.

Exclusion Criteria

  • 1\.Subjects with poorly controlled underlying diseases such as poor control of Blood
  • Pressure (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg), poor control of blood sugar (HbA1c \> 7%).
  • 2\.Subjects with eGFR \< 30 ml/min/1\.73 m2
  • 3\.Female subjects who are pregnant or lactating, or plan to have children (a negative
  • serum or urine pregnancy test is required on the screening day for women of child\-bearing potential).
  • 4\. Subjects with diseases that may interfere with supplement absorption e.g., patients
  • with malabsorption and bowel surgery.
  • 5\. Subjects using medication that may interfere with micronutrient levels such as acid
  • suppressants, antacids, antiepileptic drugs (i.e., phenobarbital, valproic acid,
  • carbamazepine, phenytoin), and antipsychotic drugs (i.e., tricyclic antidepressants and

Outcomes

Primary Outcomes

Not specified

Similar Trials